Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: $BPTH Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia
HOUSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the enrollment and dos...
Got this from BPTH - Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia
I sold my last shares of BPTH for a tax loss sometime ago. The stock that got me into this field was Tekmira now ABUS. They got good news on their patent fight with MRNA. I have held every share of ABUS and even added recently. It may be worth following. They have some great scientific talent.
Read up before buying. This is not a recommendation to buy.
Good luck all!
Thanks for the update and history lesson.
The link says the study started in May 2016. WOW. Those were the days!!! I remember we on this message board thought we would have results by the end of 2017 and we would not only be rich but would have helped humanity overcome another scourge.
The stock hit $638 (pre 200:1 RSS adjusted). Happy days.
It would be kinda interesting to know what progress there is. How many of the 108 (if any) have actually been in treatment and if any have shown remission. I recall that it started with needing 21 (or thereabouts), how the heck did it get to 108?
The web site says:
BP1002 (Liposomal Bcl2 Antisense)
Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.
Still planning for 2017 I see - have they missed the boat?
I stick with my belief that this was a hoax from the start and any remaining stock holders (such as me) are just being strung along in the hope we don't wise up and sue. Has anyone been to the office address to see if it looks like a real operation, not just a conman and secretary living it up.
Thanks for the link, we may be waiting for some time.
Estimated Study Completion Date :December 2021
No new news for a long time. Anyone else out there. I found this on yahoo blog. https://clinicaltrials.gov/ct2/show/NCT02781883
from 12 days ago.
pretty obvious from the activity on this board that people have no faith in peter .. what a screwing he gave all the original investors with his reverse stock splits.In my investment experience I have never seen 2 reverses in a 6 month period.
I used to post here all the time, mostly trying to sound the warning cry that Peter has no idea what he is doing. I come check the board now about once every couple of months, but I don't really post much any more because Peter got exactly what he wanted from all of the reverse splits, I have next to nothing left.
Your think that does not happen more often than anyone knows. I am in for the long run. It is about time that this stock has a good run to get people back interested. Only a few post here monthly. I would say investors have lost all interest in Bio-Path.
Would that not be insider trading?
That is likely true AND the fact that PN just gave himself cheap warrants. He knew the bottom was in and something big is coming IMHO
Why the jump in PPS today? It must be because I sold all my shares.
No nibbling here! I have sold ALL my shares. I will not look at this company until a PPS of $2 or less. It looks PN and the boys priced their compensation shares too high. OOOPPPPSS!
I suspect they will be re-priced soon.
I smell a reverse stock split coming
no worries pete doesn't play golf.if he did he couldn't hit the broad side of a barn door
Not me ! I am nibbling at others - so many other potential good buys out there .
I paid for enough of PN’s golf rounds .
I have such a toxic relationship with this stock. It doesn't ever give me anything in return but I keep coming back to it. Is there reason to believe that something will change? Does the move to a new all be it expensive accounting firm change any thing in your opinions? Are any of you buying at this price?
I have such a toxic relationship with this stock. It doesn't ever give me anything in return but I keep coming back to it. Does the move to a new all be it expensive accounting firm change any thing in your opinions? Are any of you buying at this low price?
Runin, I seems to me PN is most excited about BP1003 the stat3 drug.
https://www.bostonbiomedical.com/science/targeting-cancer-cell-subsets/stat3-pathway/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2610472/
He may be right but as usual where is the urgency? PN was urgent about putting 600,000 shares aside as potential compensation for him and the employees.
There has been work on stat3 drugs for years. No human trials yet for BPTH with less than 3 years of money left. Almost a year since they knew the results on last years poster. Too busy loading up their pockets?
I have been listening to PN’s conference calls for years and I have never heard him this excited before. Things will be changing soon with this fledgling company IMHO
Results are out. Only $20 million left. Two years left to get something done.
Burn rate up to $8.6 million. Got to pay to keep good people. Thx PN.
Same old song and dance. Look out below.
When if ever is this stock a buy?
The chart looks a whole lot different a year after a big move.
Dead cat bounce, anniversary of huge move, test results coming, joint venture coming, PN retiring (we could only hope), etc. take your pick
So why the big move today, not seeing anything that supports the 15+% jump.
Another buck to downside and I may start wading in again.
More sellers of BPTH.
http://archive.fast-edgar.com/20200214/A22ZO22CZW2R39ZZ2H2F2ZYSNWAFZZ22ZI22
No, I meant from the BOD position. Perhaps they will now release news. Shorting could still happen from other entities.
SJ
I saw your post on Stocktwits and below. Excuse my ignorance but when you say that now there is no more reason for them to push the price down. Does that change your buy point of below $5.00?
Up to $4 million for PN and more dilution for the
shareholders
CALCULATION OF REGISTRATION FEE
Common Stock, $0.001 par value per share 600,000
shares (2) $ 6.33 $ 3,798,000 $ 492.98
(1) Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement is deemed to include additional shares of common stock issuable under the terms of the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan, as amended by the First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (as so amended, the “Plan”), by reason of any stock dividend, stock split, recapitalization or other similar transaction.
(2) Consists of shares of common stock issuable in respect of awards to be granted under the Plan.
(3) Estimated solely for the purpose of calculating the registration fee in accordance with Rules 457(c) and (h) promulgated under the Securities Act, based upon the average of the high and low prices of Bio-Path Holdings, Inc.’s common stock as reported on The Nasdaq Capital Market on February 11, 2020.
REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION E
Bio-Path Holdings, Inc. (the “Company”) has filed this Registration Statement to register under the Securities Act of 1933, as amended, the offer and sale of an additional 600,000 shares of common stock of the Company, par value $0.001 per share, issuable under the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan, as amended by the First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (as so amended, the “Plan”). Accordingly, the contents of the previous Registration Statement on Form S-8 (File No. 333-223111) filed by the Company with the U.S. Securities and Exchange Commission on February 20, 2018 (the “Prior Registration Statement”) relating to the Plan, including periodic reports that the Company filed after the Prior Registration Statement to maintain current information about the Company, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8. The Prior Registration Statement is currently effective.
SJ, your a smart man. I also sold most of mine in the 20’s ( which was not that much after he chewed it to the bone ). But, I nibbled a few in the teens which today was a mistake. I think I am going to just wait. Had very good luck with a few others which has set me up now . I check in once in a while and may take a run at some if it looks like something may happen. As always wish everyone here good luck !
They need to keep at least a million shares. Unless the do more financing deals another R?S in unlikely for the next 2 years.
I still believe the science has value if the patents hold up.
Presently the market cap is close to cash on hand.
You still believe!!
I would not be surprised if this went down below 5cents again and PN did a 20:1 RSS. Keep milking until the cow croaks.
Oldman, This may be a buy if we drop below $5. I may start adding some until we hit $2 bucks and then load up. I sold the majority of my shares between $21-$25.
It is becoming harder and harder to avoid the subversive thought that this was a scam right from the start. The principles have made their fortunes, all believers have lost although some clever people have made money predicting the movement and trading.
Is there anyone reading this that can drop by the offices in Texas to see if there are actually people there?
why are there only 2 post in the last month..are you all losing interest in bpth
As an old investor (both by age and by length of time in this mess) I seldom bother to check to see what is going on; when you've been 200:1 buggered what is the point? (yes, that is a whine, live with it). However I took a look today to see if the world is any closer to a cancer cure and was disappointed that the BPTH web site is three years or more out of date; it refers to:
A second study in relapsed and refractory AML patients is expected to be initiated in 2017.
and:
- Prexigebersen has also completed a Phase 1 clinical trial in patients with CML and expects to initiate enrollment before the end of 2016 for the dose-determining segment of a Phase 2 trial of prexigebersen in combination with first-line standard-of-care for CML, dasatinib.
and:
Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.
I took a quick look at the 2020 slide show :
http://www.biopathholdings.com/wp-content/uploads/2020/01/BPTH_Corp_Presentation_Jan_2020.pdf
and the results on slide 8 9 10 are what I remember (no I didn't verify) from 2017
I remember the halcion days of 2016 and 2017, it seems the company hasn't moved on since then!!! Does anyone know if they are even still working on this or are they just sitting with their thumbs up their bums enjoying a free ride until the money runs out?
Just asking.
don'tyou find it interesting that BOD has lost most of the original directors.it's now a stacked BOD that will rubber stamp anything PN wants to do.
My hope is PN realizing he is not getting any younger!
My hope is PN realizing he is not getting any younger!
Folks we are still years away from FDA approval.
Until PN gets the lion share of the 660k shares approved as compensation do you really expect a drive for FDA approval?
Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook
GlobeNewswire GlobeNewswire•January 8, 2020
HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update from several clinical development programs and a 2020 business overview.
“We enter 2020 with robust development plans to commence several key clinical trials that are expected to advance our DNAbilize antisense RNAi nanoparticle technology in a number of important oncology indications for which there are limited treatment options,” said Peter H. Nielsen, President and Chief Executive Officer of Bio-Path. “We are excited to initiate a number of important studies across our development pipeline and anticipate reporting key clinical datapoints from those studies later in the year.”
Phase 2 Study of Prexigebersen in Untreated and Refractory/Resistant Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Patients
In March 2019, Bio-Path announced a revised strategy for the Stage 2 portion of its Phase 2 clinical trial of prexigebersen in combination with frontline chemotherapy. Bio-Path’s amended Stage 2 of the Phase 2 clinical trial will treat two cohorts of patients. The first cohort is to include untreated AML patients as existed in the pre-amended trial but with the addition of untreated, high-risk MDS patients. The second cohort is to include refractory/relapsed AML patients and high-risk MDS patients. Both cohorts of patients are planned to be treated with the combination of prexigebersen, decitabine and venetoclax. The Company is finalizing amendments to add this combination treatment to Stage 2 of the Phase 2 clinical trial.
The first step in the revised strategy involved testing the safety of the combination of prexigebersen and decitabine. In November 2019, the Company announced successful completion of this safety testing in AML and MDS patients in Stage 2 of the Phase 2 clinical study. The safety segment of Stage 2 of the Phase 2 clinical trial comprised six evaluable patients who were treated with the combination of prexigebersen and decitabine. Although the combination of prexigebersen and decitabine is not the treatment currently planned for the efficacy evaluation of Stage 2 of the Phase 2 clinical trial, the efficacy profile in this safety segment of the study was very encouraging, with 50% of patients having a response, including two patients (33%) showing complete responses with incomplete hematologic recovery and one patient (17%) showing partial response. For reference, in this class of AML and MDS patients, the complete response rate to treatment with decitabine alone is approximately 20%. Some patients are continuing to receive treatment.
The next step in this Stage 2 of the Phase 2 program will be the safety testing of prexigebersen in combination with decitabine and venetoclax in six evaluable patients drawn from either of the two cohorts of untreated AML and high-risk MDS patients or relapsed/refractory AML and high-risk MDS patients. The Company currently expects to initiate this safety testing in the second quarter of 2020. Assuming successful completion of this safety testing, the Company plans that it would then initiate the efficacy testing of this triple combination in the two cohorts of patients. In 2020, Bio-Path intends to continue its efforts to expand the number of sites, including European-based sites, to enhance patient enrollment.
The clinical design of the Stage 2 portion of the Phase 2 clinical trial calls for an interim analysis of each cohort’s results after each cohort has treated 19 evaluable patients. If the results from either or both patient cohorts exceed expectations for current standard-of-care therapy, the Company expects that plans for a pivotal trial would be discussed with the FDA.
Phase 2a Study of Prexigebersen to treat Chronic Myeloid Leukemia (CML) in Tyrosine Kinase Inhibitor Failures and Accelerated and Blast Phase CML Patients
Bio-Path plans to enroll patients in a Phase 2a clinical study of prexigebersen in combination with the frontline therapy, dasatinib, for the treatment of CML in tyrosine kinase inhibitor failures and accelerated and blast phase patients in 2020. The trial is expected to be conducted at The University of Texas MD Anderson Cancer Center as a potential salvage therapy for accelerated and blast phase CML patients and will expand to other sites if feasible. Recent advances in the treatment of chronic phase CML patients with tyrosine inhibitors has limited the availability of these patients for the Bio-Path Phase 2a. As a result, the continuation of this study is being evaluated based on the potential for patient availability and clinical trial site expansion. If this Phase 2a study is advanced, it will evaluate two cohorts of three evaluable patients at two doses (60 mg/m2 and 90 mg/m2) of prexigebersen in combination with dasatinib.
Phase 1 Study of Prexigebersen in Patients with Advanced Solid Tumors
In late 2019, Bio-Path filed an Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of prexigebersen in patients with advanced solid tumors, including ovarian and uterine, pancreatic and breast cancer. This trial is expected to commence after the IND has been cleared by the FDA, which we currently anticipate being in 2020, at several leading cancer centers and will evaluate the safety of prexigebersen in these patients. Assuming positive Phase 1 results, the Company expects it would advance to a Phase 1b clinical trial of prexigebersen in combination with frontline therapy in these same advanced solid tumor patients.
Phase 1 Study of BP1002 in Refractory or Relapsed Lymphoma Patients and Chronic Lymphocytic Leukemia Patients
In November 2019 the FDA cleared the IND for BP1002 (liposomal Bcl-2), the Company’s second drug candidate, to begin a Phase 1 clinical trial to evaluate BP1002 as a treatment for refractory/relapsed lymphoma and chronic lymphocytic leukemia patients. This study is expected to commence in the first half of 2020 and is expected to be conducted at several premier oncology centers, including the University of Texas MD Anderson Cancer Center, and is planned to evaluate the safety of BP1002 in several dose escalating cohorts to determine a maximum tolerated dose.
Preclinical Development of BP1003
The Company continues to advance its third investigational drug candidate, BP1003, for the treatment of advanced solid tumors, including pancreatic cancer. BP1003 is an antisense RNAi nanoparticle targeting the Stat3 protein.
In 2020 Bio-Path expects to complete several IND-enabling studies for BP1003. If those studies are successful, Bio-Path expects that it would file an IND in late 2020 for the first-in-humans Phase 1 study of BP1003 in patients with refractory/metastatic solid tumors including pancreatic, non-small cell lung cancer, and colorectal cancers.
BP1003 has demonstrated efficacy in combination with frontline therapies in animals against pancreatic tumors.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies.For more information, please visit the Company's website at http://www.biopathholdings.com.
The FDA approves a new drug for pancreatic cancer. Where is BPTH's drug?
https://www.ibtimes.com/fda-approves-one-kind-drug-treating-advanced-pancreatic-cancer-2894114
One thing is certain. PN certainly makes sure he is paid.
Increase shareholder dilution by 23% to get paid.
The fox is in the hen house again.
The BOD diluting the float for their own gain.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Bio-Path Holdings, Inc. (the “Company”) held its 2019 annual meeting (the “2019 Annual Meeting”) of stockholders of the Company on December 19, 2019 in The Woodlands, Texas. At the 2019 Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (the “2017 Plan”) to increase the number of shares of the Company’s common stock that may be issued under the 2017 Plan by 600,000 shares for a total of 660,000 shares. A description of the 2017 Plan is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 1, 2019 under the heading “Proposal Two: Approval Of An Amendment To The Company’s 2017 Stock Incentive Plan To Increase The Number Of Shares Of Common Stock That May Be Issued Under The Plan By 600,000 Shares For A Total Of 660,000 Shares,” which description is incorporated herein by reference. This summary is qualified in its entirety by the full text of the Amendment, which is filed as Exhibit 10.1 hereto, and the 2017 Plan, which is filed as Exhibit 10.2 hereto.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2019 Annual Meeting, the Company’s stockholders: (i) elected the five persons listed below under Proposal 1 to serve as directors of the Company, to hold office until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified; (ii) approved the Amendment to the 2017 Plan; (iii) approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers; (iv) approved, on a non-binding advisory basis, the frequency of “every three years” for the stockholders’ non-binding advisory vote on the compensation of the Company’s named executive officers; and (v) ratified and approved the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2019. The following describes the results of the voting at the 2019 Annual Meeting:
Proposal 1: For the election of directors of the Company, to hold office until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified:
Peter H. Nielsen 326,250 -- 30,833 -- 1,790,089
Heath W. Cleaver 321,104 -- 35,979 -- 1,790,089
Paul D. Aubert 321,532 -- 35,551 -- 1,790,089
Martina Molsbergen 331,191 -- 25,892 -- 1,790,089
Douglas P. Morris 331,836 -- 25,247 -- 1,790,089
Proposal 2: For the approval of the Amendment to the 2017 Plan:
214,416 139,538 -- 3,129 1,790,089
Proposal 3: For the non-binding advisory approval of the compensation of the Company’s named executive officers:
304,230 46,537 -- 6,316 1,790,089
Proposal 4: For the non-binding advisory approval of the frequency of stockholders’ non-binding advisory vote on the compensation of the Company’s named executive officers:
101,550 85,884 160,402 9,247
Proposal 5: For the ratification and approval of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2019:
2,049,920 54,045 -- 43,207 --
Based on the stockholders’ advisory vote and other factors, the board of directors of the Company resolved that future non-binding stockholder advisory votes on the compensation of the Company’s named executive officers will be conducted every three years until such time as the Company holds another stockholder advisory vote on the frequency of advisory votes by the stockholders on the compensation of the Company’s named executive officers.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-PATH HOLDINGS, Inc.
Dated: December 23, 2019 By: /s/ Peter H. Nielsen
Peter H. Nielsen
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number Description
10.1 First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan
10.2 Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 27, 2017).
--------------------------------------------------------------------------------
Exhibit 10.1
FIRST AMENDMENT
TO
BIO-PATH HOLDINGS, INC.
2017 STOCK INCENTIVE PLAN
This First Amendment (the “First Amendment”) to that certain Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (the “Plan”) of Bio-Path Holdings, Inc., a Delaware corporation (the “Company”), is adopted as of October 28, 2019, subject to the approval of the stockholders of the Company. All capitalized and undefined terms used herein shall have the meanings ascribed to such terms in the Plan.
WHEREAS, pursuant to subsection 18.1 of the Plan, the Board of Directors of the Company (the “Board”) is authorized to amend the Plan, provided that any amendment that would increase the number of Shares reserved for issuance under the Plan (other than in accordance with an adjustment pursuant to subsection 17.1 of the Plan) must be approved by the stockholders of the Company within twelve (12) months before or after such amendment; and
WHEREAS, the Board unanimously approved this First Amendment to increase the number of Shares reserved for issuance under the Plan as set forth herein, subject to the approval of the stockholders of the Company, and has recommended that the stockholders of the Company approve this First Amendment.
NOW, THEREFORE, in connection with the foregoing, the Plan is hereby amended as follows, subject to approval by the stockholders of the Company:
Subsection 4.1 is hereby deleted in its entirety and replaced with the following:
1. “4.1 Share Reserve. Except as otherwise provided in this Section 4 and subsection 17.1, the maximum number of Shares that may be issued with respect to Awards granted pursuant to this Plan shall not exceed 660,000. All or any portion of the Share reserve may be issued in connection with the exercise of Incentive Stock Options. The Shares issued pursuant to this Plan may be authorized but unissued Shares or may be issued Shares that have been repurchased or acquired by the Company, including shares purchased by the Company on the open market for purposes of the Plan.”
Except as amended and modified by this First Amendment, the Plan shall continue in full force and effect, and the Plan and this First Amendment shall be construed as one and the same instrument.
The foregoing is hereby acknowledged as being the First Amendment to the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan, as adopted by the Board on October 28, 2019, subject to approval by the Company’s stockholders.
BIO-PATH HOLDINGS, INC.
By: /s/ Peter H. Nielsen
Name: Peter H. Nielsen
Title: President and Chief Executive Officer
HC Wainwright had it at 28.00, but then revised it to 25.00. BPTH having a good move today, but I see no news that is boosting price. Volume heavy.
who has the 28 target ?
With all these analyst's upgrades, why is this stock not moving?? Price targets of 25 and 28 should have given the stock a nice "sustaining" bump.
Trial listed
https://clinicaltrials.gov/ct2/show/NCT04196257
BPTH volume in trading and stocktwits posts both declining by day.
Followers
|
102
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6389
|
Created
|
03/26/13
|
Type
|
Free
|
Moderators |
The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.
Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive.
A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson.
Patent protection for manufacturing their neutral lipid delivery system has been granted.
http://www.biopathholdings.com
This link to the company website describes their delivery technology:
http://biopathholdings.com/technology/
The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 2+ million in cash. BIO-PATH'S viability is in question due to a lack of funds.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |